New drug aims to clear skin completely in psoriasis patients

NCT ID NCT07090330

Ongoing Disease control Sponsor: Oruka Therapeutics, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing an experimental drug called ORKA-001 for people with moderate-to-severe plaque psoriasis. Researchers want to see if the drug can completely clear skin symptoms and maintain that improvement over a year. The study involves 80 adults who will receive either the drug or a placebo for 52 weeks, with an option to continue in an extension study.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Oruka Therapeutics Investigative Site

Fountain Valley, California, 92708, United States
Oruka Therapeutics Investigative Site

Los Angeles, California, 90045, United States
Oruka Therapeutics Investigative Site

San Diego, California, 92123, United States
Oruka Therapeutics Investigative Site

Santa Ana, California, 92701, United States
Oruka Therapeutics Investigative Site

Santa Monica, California, 90404, United States
Oruka Therapeutics Investigative Site

Cromwell, Connecticut, 06416, United States
Oruka Therapeutics Investigative Site

Coral Gables, Florida, 33134, United States
Oruka Therapeutics Investigative Site

Rolling Meadows, Illinois, 60008, United States
Oruka Therapeutics Investigative Site

Bowling Green, Kentucky, 42104, United States
Oruka Therapeutics Investigative Site

Rockville, Maryland, 20850, United States
Oruka Therapeutics Investigative Site

Boston, Massachusetts, 02111, United States
Oruka Therapeutics Investigative Site

Detroit, Michigan, 48202, United States
Oruka Therapeutics Investigative Site

New York, New York, 10023, United States
Oruka Therapeutics Investigative Site

New York, New York, 10029, United States
Oruka Therapeutics Investigative Site

Portland, Oregon, 97201, United States
Oruka Therapeutics Investigative Site

Norfolk, Virginia, 23502, United States
Oruka Therapeutics Investigative Site

Milwaukee, Wisconsin, 53226, United States
Oruka Therapeutics Investigative Site

Edmonton, Alberta, T5J 3S9, Canada
Oruka Therapeutics Investigative Site

Edmonton, Alberta, T6G 1C3, Canada
Oruka Therapeutics Investigative Site

Surrey, British Columbia, V3R 6A7, Canada
Oruka Therapeutics Investigative Site

Hamilton, Ontario, L8N 1Y2, Canada
Oruka Therapeutics Investigative Site

London, Ontario, N6H 5LS, Canada
Oruka Therapeutics Investigative Site

Markham, Ontario, L3P 1X3, Canada
Oruka Therapeutics Investigative Site

Peterborough, Ontario, K9J 5K2, Canada
Oruka Therapeutics Investigative Site

Toronto, Ontario, M4W 2N4, Canada
Oruka Therapeutics Investigative Site

Waterloo, Ontario, N2J 1C4, Canada

Conditions

Explore the condition pages connected to this study.

PLAQUE PSORIASIS